Dogwood Therapeutics (DWTX)

• Market cap: $98.5M
• 1 day: -6.4%
• 5 days: 8.1%
• 1 month: -26.9%
• 3 months: -51.11%
• 6 months: -36.31%
• Year to date: -27.59%
• 1 year: -79.61%
• 5 years: -98.29%
• 10 years: -99.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Employees: 12